CYP2D6 structural variants were observed in 13 percent of patients. A majority of these structural variants (73 percent) are known to confer decreased or no CYP2D6 function.

The researchers found higher breast cancer event rates in patients with reduced or absent CYP2D6 function vs. extensive metabolism patients. "At 9 years of follow-up, the recurrence rates were 14. ...

Of the 3 beta-blockers recommended for use in HF patients, 2 are metabolized by CYP2D6, “a highly polymorphic enzyme of the P450 family.” Because of this, these agents are subject to varying ...

Commercial tests for CYP2D6 genotyping are available, and some experts have argued that they should be used in clinical practice, particularly in the case of postmenopausal women, where there is ...